1
|
Hass R, Lueck H, von Wasielewski R, Jin H, Pich A, Kuehnle H, Grothuesmann D, Hille U, Bertram C. Altered chemotherapeutic response of primary human breast cancer epithelial cells (HBCEC) and breast cancer cell lines. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.11506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11506 Background: A novel technique to obtain individual primary cultures of human breast cancer biopsies was filed for patent (PCT/DE 2006/000608). The different individualized HBCEC (human breast cancer epithelial cell) cultures will be characterized and chemotherapeutic effects will be compared to established breast cancer cell lines. Methods: Primary HBCEC from 20 different breast cancer patients were characterized for epithelial cell and tumor markers by immunofluorescence and PCR. Following treatment with 1μM epirubicin for 1h up to 72h differences in protein expression patterns were compared to the similarly treated MCF-7 cell line by 2D gel electrophoresis. Differentially expressed protein spots were identified by mass spectrometry and confirmed by appropriate Western blot analysis. Results: Characterization of primary HBCEC revealed continuous mitosis and cell cycle progression for more than one year in culture with no significant contamination by fibroblasts or other cell types. Whereby HBCEC underwent cell death within 72h of epirubicin treatment analysis by 2D gel and subsequent protein identification by MALDI-TOF/TOF mass spectrometry exhibited a variety of differences compared to MCF-7 cells including HSP27 and prohibitin. Appropriate Western blots confirmed these differences and revealed altered expression levels for HSP27 and prohibitin in the course of epirubicin exposure in HBCEC and MCF-7 cells, respectively, suggesting altered signalling pathways in either primary breast cancer cells or the tumor cell line. Conclusions: Individualized primary HBCEC from various patients could provide a cellular platform beyond breast cancer cell lines, which eventually meet the requirements for an appropriate breast cancer testing system including the characterization of biomarkers and the identification of potential molecular targets. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. Hass
- Medical School, Hannover, Germany; Dr. Horst Schmidt Klinik, Wiesbaden, Germany
| | - H. Lueck
- Medical School, Hannover, Germany; Dr. Horst Schmidt Klinik, Wiesbaden, Germany
| | - R. von Wasielewski
- Medical School, Hannover, Germany; Dr. Horst Schmidt Klinik, Wiesbaden, Germany
| | - H. Jin
- Medical School, Hannover, Germany; Dr. Horst Schmidt Klinik, Wiesbaden, Germany
| | - A. Pich
- Medical School, Hannover, Germany; Dr. Horst Schmidt Klinik, Wiesbaden, Germany
| | - H. Kuehnle
- Medical School, Hannover, Germany; Dr. Horst Schmidt Klinik, Wiesbaden, Germany
| | - D. Grothuesmann
- Medical School, Hannover, Germany; Dr. Horst Schmidt Klinik, Wiesbaden, Germany
| | - U. Hille
- Medical School, Hannover, Germany; Dr. Horst Schmidt Klinik, Wiesbaden, Germany
| | - C. Bertram
- Medical School, Hannover, Germany; Dr. Horst Schmidt Klinik, Wiesbaden, Germany
| |
Collapse
|
2
|
Rossner D, Knobloch K, Lichtinghagen R, Lichtenberg A, Kuehnle H, Lueck HJ. NT-pro-BNP and CA 125 as potential markers of mortality during long-term immunetherapy with trastuzumab in HER-2-positive metastatic breast cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. Rossner
- Gynecologic Oncology, Hannover, Germany; Thoracic and cardiovascular surgery, Hannover, Germany; Clinical Chemistry, Medical School, Hannover, Germany
| | - K. Knobloch
- Gynecologic Oncology, Hannover, Germany; Thoracic and cardiovascular surgery, Hannover, Germany; Clinical Chemistry, Medical School, Hannover, Germany
| | - R. Lichtinghagen
- Gynecologic Oncology, Hannover, Germany; Thoracic and cardiovascular surgery, Hannover, Germany; Clinical Chemistry, Medical School, Hannover, Germany
| | - A. Lichtenberg
- Gynecologic Oncology, Hannover, Germany; Thoracic and cardiovascular surgery, Hannover, Germany; Clinical Chemistry, Medical School, Hannover, Germany
| | - H. Kuehnle
- Gynecologic Oncology, Hannover, Germany; Thoracic and cardiovascular surgery, Hannover, Germany; Clinical Chemistry, Medical School, Hannover, Germany
| | - H. J. Lueck
- Gynecologic Oncology, Hannover, Germany; Thoracic and cardiovascular surgery, Hannover, Germany; Clinical Chemistry, Medical School, Hannover, Germany
| |
Collapse
|
3
|
Kuehnle H, Meerpohl HG, Eiermann W, Achterrath W. Neoadjuvant therapy for cervical cancer. Semin Oncol 1992; 19:94-8. [PMID: 1411633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The stage-by-stage prognosis for cervical cancer patients has not improved in the past decades. Our research work concerning adjuvant chemotherapy for the early stages induced a pilot study with untreated patients in advanced stages. Patients were treated with carboplatin 300 mg/m2 plus ifosfamide 5 g/m2 on day 1. In cases of remission or no change, the therapy was repeated after 4 weeks. A third course was given only after further remission. After chemotherapy, patients were treated with surgery or radiotherapy according to feasibility. A total of 34 patients were admitted to this study. Thirty-two patients with 88 chemotherapy courses were evaluable for response and toxicity. Nineteen patients achieved remission; three achieved complete remission. The most common toxic effects were myelosuppression with grade four leukopenia (28%) and thrombocytopenia (13%). Alopecia (60%) was the main nonhematologic toxicity. In conclusion, we suggest that this regimen is as effective as other platin-containing regimens for squamous cell carcinoma of the cervix uteri, but its hematologic toxicity precludes its recommendation in an adjuvant setting.
Collapse
Affiliation(s)
- H Kuehnle
- Department of Gynecology and Obstetrics, Hannover University, Germany
| | | | | | | |
Collapse
|